AIM SEC Filings: 8-K, 10-Q, S-3 & 424B – AIM ImmunoTech

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 27, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 17, 2025

NT 10-Q

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Nov 17, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

AIM ImmunoTech Highlights Potential for Ampligen to Complement RAS-Targeted Therapies in Pancreatic Cancer

Nov 5, 2026

8-K

AIM ImmunoTech Enters Exchange Agreements to Convert Promissory Note Debt into Common Stock

Sep 14, 2026

8-K

AIM ImmunoTech Enters Exchange Agreements to Convert Promissory Note into Common Stock

Sep 10, 2026

8-K

AIM ImmunoTech Inc. Satisfies Promissory Note Through Debt-for-Equity Exchange

Sep 4, 2026

8-K

Biodefense Is Force Protection: AIM ImmunoTech CEO Advocates for Proactive Viral Countermeasures

Aug 11, 2026

8-K

AIM ImmunoTech Reports Q2 2026 Financial Results and Progress on Ampligen® Pancreatic Cancer Program

Aug 10, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Shares: 13,077,089 | Bank: Ladenburg Thalmann & Co., Inc.

Jun 24, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 31,287,933 | Bank: Ladenburg Thalmann & Co., Inc.

Jun 18, 2026

424B5

REGISTERED OFFERING

Jun 10, 2026

424B5

REGISTERED OFFERING

May 21, 2026

424B5

TERMINATED/EXPIRED May 2026 ATM | Offering amount: $3,409,174 | Bank: Maxim Group LLC

May 19, 2026

424B5

April 2026 ATM | Offering amount: $3,409,174 | Bank: Maxim Group LLC

Apr 10, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 9, 2026

S-1

SHARE RESALE REGISTRATION

Jun 18, 2026

S-1

SHARE RESALE REGISTRATION

Jun 8, 2026

S-1/A

OFFERING

Feb 10, 2026

S-1/A

OFFERING - BEST EFFORTS | Bank: Maxim Group LLC

Jan 29, 2026

S-1/A

OFFERING - BEST EFFORTS | Bank: Maxim Group LLC

Jan 23, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Nov 3, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Sep 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jun 25, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Jun 15, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 2, 2025

Ownerships

TYPE

HEADLINE

FILED AT

NEWEquels Thomas K (Reporting)

Nov 9, 2026

Equels Thomas K (Reporting)

Nov 6, 2026

Equels Thomas K (Reporting)

Oct 26, 2026

Equels Thomas K (Reporting)

Oct 23, 2026

Equels Thomas K (Reporting)

Sep 18, 2026

Equels Thomas K (Reporting)

Sep 17, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 24, 2026

CORRESP

Form CORRESP - Correspondence

Jun 18, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jun 18, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 17, 2026

CORRESP

Form CORRESP - Correspondence

Jun 15, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jun 12, 2026

AIM ImmunoTech Inc. AIM · SEC Filings